JP2024516829A - エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 - Google Patents

エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 Download PDF

Info

Publication number
JP2024516829A
JP2024516829A JP2023566519A JP2023566519A JP2024516829A JP 2024516829 A JP2024516829 A JP 2024516829A JP 2023566519 A JP2023566519 A JP 2023566519A JP 2023566519 A JP2023566519 A JP 2023566519A JP 2024516829 A JP2024516829 A JP 2024516829A
Authority
JP
Japan
Prior art keywords
compound
composition
edonentan
biodegradable polymer
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516829A5 (https=
Inventor
チェン－ウェン リン，
アンジェラ ドーン グレンデニング，
セヴギ ギュルカン，
Original Assignee
パフューズ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パフューズ セラピューティクス， インコーポレイテッド filed Critical パフューズ セラピューティクス， インコーポレイテッド
Publication of JP2024516829A publication Critical patent/JP2024516829A/ja
Publication of JP2024516829A5 publication Critical patent/JP2024516829A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023566519A 2021-04-30 2022-04-29 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 Pending JP2024516829A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182750P 2021-04-30 2021-04-30
US63/182,750 2021-04-30
PCT/US2022/027045 WO2022232586A1 (en) 2021-04-30 2022-04-29 Treatment of ocular diseases using endothelin receptor antagonists

Publications (2)

Publication Number Publication Date
JP2024516829A true JP2024516829A (ja) 2024-04-17
JP2024516829A5 JP2024516829A5 (https=) 2025-05-12

Family

ID=83848733

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566519A Pending JP2024516829A (ja) 2021-04-30 2022-04-29 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置

Country Status (9)

Country Link
US (1) US20240058265A1 (https=)
EP (1) EP4329810A4 (https=)
JP (1) JP2024516829A (https=)
CN (1) CN117295520A (https=)
AU (1) AU2022264438A1 (https=)
CA (1) CA3218398A1 (https=)
IL (1) IL307794A (https=)
MX (1) MX2023012826A (https=)
WO (1) WO2022232586A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4329753A4 (en) * 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082285A1 (en) * 2000-12-21 2002-06-27 Lebwohl David E. Method for preventing or treating pain by administering an endothelin antagonist
JP2009535422A (ja) * 2006-05-04 2009-10-01 アラーガン、インコーポレイテッド 血管作動薬を含有する持続放出性眼内インプラント

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1013904A2 (pt) * 2009-04-30 2016-07-19 Univ Midwestern método e composição para tratar cetoacidose diabética
US20120087864A1 (en) * 2010-04-12 2012-04-12 R-Tech Ueno, Ltd. Method for diagnosing and/or evaluating retinal disease
CA2949954A1 (en) * 2014-05-23 2015-11-26 Ocular Technologies Sarl Topical formulations and uses thereof
WO2018185516A1 (en) * 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
JP2020528082A (ja) * 2017-07-17 2020-09-17 ロイズマン，キース 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達
EP4050997A4 (en) * 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS
CA3168810A1 (en) * 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
EP4329753A4 (en) * 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082285A1 (en) * 2000-12-21 2002-06-27 Lebwohl David E. Method for preventing or treating pain by administering an endothelin antagonist
JP2009535422A (ja) * 2006-05-04 2009-10-01 アラーガン、インコーポレイテッド 血管作動薬を含有する持続放出性眼内インプラント

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NATESAN MURUGESAN ET AL.: ""Biphenylsulfonamide Endothelin Receptor Antagonists. 4. Discovery of N-[[2‘-[[(4,5-Dimethyl-3-isox", JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 1, JPN6026010199, 2003, pages 125 - 137, ISSN: 0005816579 *
SAEED F. ALRASHDI ET AL.: ""Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists", EXPERIMENTAL EYE RESEARCH, vol. 176, JPN6026010198, 2018, pages 1 - 9, ISSN: 0005816578 *

Also Published As

Publication number Publication date
MX2023012826A (es) 2023-11-13
US20240058265A1 (en) 2024-02-22
WO2022232586A1 (en) 2022-11-03
EP4329810A4 (en) 2025-02-26
EP4329810A1 (en) 2024-03-06
CN117295520A (zh) 2023-12-26
IL307794A (en) 2023-12-01
CA3218398A1 (en) 2022-11-03
AU2022264438A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
TWI752083B (zh) 醫藥組合物
JP7664239B2 (ja) エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
US20220023213A1 (en) Nanocrystalline eye drop, preparation method and use thereof
KR102766771B1 (ko) 국소형 시클로스포린 함유 제형 및 그의 용도
US11786510B2 (en) Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
KR20220143685A (ko) 안질환의 치료를 위한 조성물
CN107454841A (zh) 内皮素受体拮抗剂的局部眼用制剂及其用途
US20240058265A1 (en) Treatment of ocular diseases using endothelin receptor antagonists
US20070167526A1 (en) Topical mecamylamine formulations for ocular administration and uses thereof
EP1867334A1 (en) Method of relieving or avoiding side effect of steroid compound
HK40085602A (en) Treatment of ocular diseases using endothelin receptor antagonists
WO2025137007A1 (en) Methods of preparing drug delivery systems for the treatment of ocular diseases
WO2025137005A1 (en) Methods of preparing drug delivery systems for the treatment of ocular diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260316

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260318